Parameter
| Biomarker | CTLA-4 | Full name | Cytotoxic T-lymphocyte-associated protein 4 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis |
| Disease | Breast Cancer | Disease Subtypes | / | ||
| Organ | Breast | Test Sample / Technology Platform | CTLA tumor tissue (IHC), peripheral blood T cells (flow cytometry) | ||
| Pathobiological Mechanisms | CTLA-4 is expressed on the surface of activated T cells. By inhibiting T cell activation, it negatively regulates anti-tumor immunity and leads to tumor immune escape. | ||||
| Clinical Availability Status | Clinical application (immunotherapy guidance): CTLA-4 inhibitors (such as ipilimumab) have been approved for the treatment of advanced triple-negative breast cancer (in combination with PD-1 inhibitors) | ||||
| Notes and Dynamics | The expression level of CTLA-4 can predict the response to immunotherapy. Patients with high expression are more likely to benefit from immunotherapy combined treatment. | ||||